AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06027840
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
Trial: NCT05533775
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Trial: NCT05533775
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Trial: NCT05533775
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Trial: NCT05533775
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Trial: NCT06015880
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06015880
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04629248
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
Trial: NCT04629248
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
Trial: NCT04629248
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Trial: NCT04629248
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Trial: NCT06393127
Drug: BI 1015550 Formulation C2
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550 Formulation C2
Trial: NCT06393127
Drug: BI 1015550 Formulation C1
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550 Formulation C1
Trial: NCT05515315
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
Trial: NCT05515315
Drug: Albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
Trial: NCT05515315
Drug: Nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
Trial: NCT05303064
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
Trial: NCT05823311
Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
Trial: NCT05823311
Drug: Gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
Trial: NCT04963088
Drug: BGB-A317
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
Trial: NCT04963088
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration daily d1-d14, q3w;
Trial: NCT04963088
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
Trial: NCT05806021
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
Trial: NCT04690270
Drug: Sumatriptan 100 mg
RxNorm normalized name: sumatriptan 100 MG
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose Sumatriptan 100 mg
Trial: NCT06384222
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT06384222
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT06537596
Drug: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
RxNorm normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single administration of 89Zr-TLX300-CDx
Trial: NCT06201559
Drug: Albendazole IP 400 mg
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole IP 400 mg tablets will be administered under fed conditions
Trial: NCT06201559
Drug: Albendazole 400 mg
RxNorm normalized name: albendazole 400 MG
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg tablets will be administered under fed conditions
Trial: NCT05067257
Drug: Resiniferatoxin
RxNorm normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiniferatoxin is a compound purified from natural sources
Trial: NCT00002175
Drug: Dinitrochlorobenzene
RxNorm normalized name: Dinitrochlorobenzene
DrugBank: Dinitrochlorobenzene (DB11831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06567808
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration as outlined
Trial: NCT06567808
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered as outlined
Trial: NCT06511908
Drug: (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
RxNorm normalized name: undecylenate
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 and 2 Experimental Intervention
Trial: NCT00002315
Drug: Netivudine
RxNorm normalized name: Netivudine
DrugBank: Netivudine (DB12606)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002315
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06122649
Drug: apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT03938467
Drug: Antiseptic Cleanser
RxNorm normalized name: Antiseptic Cleanser
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
Trial: NCT06536374
Drug: Trimethoprim Tablets
RxNorm normalized name: Trimethoprim Tablets
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim 150mg is administered once daily for 3 months
Trial: NCT04122105
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
Trial: NCT05026983
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05026983
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05771012
Drug: 0.05% cyclosporin (Restasis®, Allergan Inc)
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
Trial: NCT04783766
Drug: CK-3773274
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CK-3773274- Tablets
Trial: NCT06057519
Drug: Optimised dose rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimized dose of rifampicin
Trial: NCT00409019
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study cancelled: Withdrawn before enrollment of any participants
Trial: NCT00409019
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00409019
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06289998
Drug: Tamibarotene
RxNorm normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
Trial: NCT06504459
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT06504459
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06504459
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given SC
Trial: NCT06504459
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05325099
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
Trial: NCT05803018
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05316675
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isotretinoin 13-cis-retinoic acid), derived from vitamin A
Trial: NCT05163496
Drug: Psilocybin (Usona Institute)
RxNorm normalized name: vilanterol
DrugBank: Psilocybin (DB11664)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAP + psilocybin 25 mg
Trial: NCT05712096
Drug: EVUSHELD
RxNorm normalized name: Evusheld
DrugBank: Cilgavimab (DB16393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
Trial: NCT05727891
Drug: Tonabersat
RxNorm normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Trial: NCT05807048
Drug: Daratumumab and Hyaluronidase-fihj
RxNorm normalized name: daratumumab-fihj / hyaluronidase-fihj Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
Trial: NCT05042336
Drug: camrelizumab/lenvatinib combined with TACE
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w
Trial: NCT05807048
Drug: Post-Intervention Medication
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment.
Trial: NCT05635045
Drug: I 124-Evuzamitide
RxNorm normalized name: IODINE I 124 EVUZAMITIDE
DrugBank: Iodine I-124 Evuzamitide (DB18394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Trial: NCT06392230
Drug: Oral PF-06821497
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
Trial: NCT06392230
Drug: IV [14C] PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
Trial: NCT06442761
Drug: Motixafortide
RxNorm normalized name: Motixafortide
DrugBank: Motixafortide (DB14939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Subcutaneously (under the skin).
Trial: NCT05309616
Drug: Taltz
RxNorm normalized name: Taltz
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
Trial: NCT05588388
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
Trial: NCT05496036
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg IV
Trial: NCT04734080
Drug: Dronabinol 5mg Cap
RxNorm normalized name: DRONABINOL 5MG CAP
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
Trial: NCT05904912
Drug: PENG-Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
Trial: NCT05904912
Drug: Local infiltration-Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
Trial: NCT05335629
Drug: Dapagliflozin 10Mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
Trial: NCT04661397
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
Trial: NCT04661397
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
Trial: NCT04661397
Drug: Emtricitabine/Tenofovir Alafenamide
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
Trial: NCT04661397
Drug: Cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
Trial: NCT06155604
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg daily
Trial: NCT05586061
Drug: Disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
Trial: NCT05586061
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
Trial: NCT05586061
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
Trial: NCT04515394
Drug: Tepotinib
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
Trial: NCT05331651
Drug: Glycopyrronium in Combination With Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
Trial: NCT05137080
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24mg dexamethasone
Trial: NCT05331651
Drug: Normal Saline in Combination With Tropisetron
RxNorm normalized name: NS-2359
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.